Core Viewpoint - The company, known for transforming traditional pharmaceutical distribution through the internet, has seen its stock price plummet below its initial offering price despite revenue and profit growth, indicating a fundamental failure in its business model [1][6]. Business Model Transformation - Founded in 2015, the company aimed to create a digital platform connecting drug suppliers with pharmacies to address information asymmetry and channel chaos in the outpatient pharmaceutical market [7]. - The traditional pharmaceutical distribution model is linear, leading to high end-user prices due to markups at each stage [8]. - The company proposed a "flattening" of this process, allowing pharmacies to connect directly with suppliers through its platform, embodying typical internet platform thinking [9]. - However, increased competition and capital pressure led to a shift towards a "platform + self-operated" dual model, where self-operated business began to dominate, accounting for 94.67% of operations by mid-2024 [10]. - The self-operated business model relies on using supplier data to produce competing products, undermining trust in the platform [11]. Stock Price Decline - The stock price has dramatically fallen from a peak of 64.5 HKD in August 2023 to 5.62 HKD, resulting in a market value loss of over 30 billion HKD [12]. - The decline began on December 13, 2023, coinciding with the lifting of a lock-up period for pre-IPO shareholders, leading to a 46% drop in a single day [13]. - This capital exodus reflects a complete loss of confidence in the company's business model, exacerbated by new regulatory requirements [13][15]. Strategic Positioning - The company positions itself as a "digital comprehensive service platform for the outpatient pharmaceutical industry," but fundamentally remains a traditional pharmaceutical distributor [18]. - Unlike competitors like JD Health and Alibaba Health, which leverage real supply chain capabilities, the company struggles with logistics and lacks direct cooperation with pharmaceutical companies [20]. - The company's strategic direction has been inconsistent, attempting to expand into various areas, which has diluted focus and resources [22]. Financial Performance - Financially, the company appears to be improving, with a net profit of 150.81 million in 2024 and 78.117 million in the first half of 2025 [23]. - However, the growth is based on a fragile foundation, with self-operated business gross margins at only 5.9%, while platform business margins are significantly higher at 84.2% [24]. - The reliance on high sales volume for profitability is concerning, with a net profit margin of only 0.08% in 2024 [25]. - Cash flow remains under pressure despite reported profits, raising concerns about sustainability [26]. Industry Insights - The case of the company highlights the importance of compliance in the pharmaceutical industry, emphasizing that digitalization must not bypass essential regulations [29]. - The industry must focus on building compliant supply chains and enhancing efficiency rather than attempting to circumvent regulations [30]. - Future competition in the pharmaceutical e-commerce sector will hinge on supply chain stability, service professionalism, and data authenticity, rather than mere price competition [33].

Core Viewpoint - The stock of Yaoshi Bang (09885) has seen a significant increase of over 9%, currently trading at 10.55 HKD with a transaction volume of 320 million HKD, driven by positive research from CITIC Securities [1] Group 1: Business Performance - Yaoshi Bang launched its brand-first business in 2020, targeting high-demand product categories and partnering with upstream manufacturers to supply to grassroots medical institutions and pharmacies, achieving an excess gross margin [1] - The GMV of the brand-first business grew by 115.6% year-on-year to 1.08 billion CNY in the first half of 2025, with the self-owned brand GMV increasing by 473.4% year-on-year to 852 million CNY [1] - CITIC Securities believes that the company will continue to steadily increase the proportion of high-margin business, especially after acquiring a pharmaceutical segment that enriches its self-owned product matrix, potentially leading to additional growth [1] Group 2: Product Development and Market Expansion - In 2024, the company plans to launch three "Future Spectrum" series POCT devices, focusing on the grassroots medical institution market to enhance its basic disease detection capabilities [1] - As of June 30, 2025, the company has covered over 18,000 terminal institutions and deployed more than 23,000 units, with plans for accelerated deployment in the second half of 2025 [1] - The POCT devices will be integrated with the clinic's digital management system ("Spectrum Cloud Diagnosis" SaaS system) and AI-assisted systems (Spectrum Smart Doctor), aiming to improve clinic operations and user engagement [1] - The company is actively advancing the application of AI and robotics technology to enhance downstream customer empowerment and supply chain efficiency, which is expected to drive further growth [1]

Core Viewpoint - The stock of Yaoshi Bang (09885) has seen a significant increase of over 9%, driven by strong growth in its proprietary brand business and the introduction of new medical devices aimed at grassroots healthcare institutions [1][2] Group 1: Financial Performance - Yaoshi Bang's proprietary brand business GMV grew by 115.6% year-on-year to 1.08 billion yuan in the first half of 2025, with the higher-margin self-owned brand GMV increasing by 473.4% to 852 million yuan [1] - The company has achieved a trading volume of 320 million Hong Kong dollars, reflecting strong market interest [1] Group 2: Product Development and Market Strategy - In 2024, the company plans to launch three new "Future Spectrum" series POCT devices, focusing on the grassroots healthcare market to enhance its disease detection capabilities [2] - As of June 2025, the company has covered over 18,000 terminal institutions and deployed more than 23,000 units of its POCT devices, with plans for accelerated deployment in the second half of 2025 [2] - The POCT devices will be integrated with the "Spectrum Cloud Diagnosis" SaaS system and AI-assisted systems, aiming to improve clinic management and user engagement [2] Group 3: Future Growth Potential - The company is actively advancing the application of AI and robotics technology to enhance downstream customer capabilities and optimize supply chain efficiency, which is expected to drive further growth [2]